Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose

Introduction into fetal rat brain cells of a replication-defective retroviral vector harboring v-Ha-ras and v-gag-myc rapidly causes the induction of highly malignant undifferentiated neuroectodermal tumors following transplantation into the brains of syngeneic hosts [Wiestler, et al. (1992) Cancer Res. 52: 3760–3767]. In the present study, we have investigated the modulating effect of the developmental stage of neural target cells and of the dose of the retroviral vector used in the grafting experiments. Exposure of fetal cells from embryonic day (E)12 or E14 produced a 100% incidence of malignant neuroectodermal tumors which led to the death of recipient animals after a median latency period of 32 days. A 100-fold reduction of the virus dose from 2.062×10⁶ to 2.062×10⁴ focus-forming units/ml resulted in a lower tumor incidence of 25%. Of six neural grafts exposed to v-Ha-ras and v-myc at E16, only one showed evidence of tumorigenesis (low-grade astrocytoma and hemangioma). All other transplants were morphologically normal for observation periods of 26 weeks, indicating a marked loss of transforming activity of ras and myc in more advanced stages of brain development. In retrovirus-exposed donor cells which caused the development of neural tumors in recipient rats, malignant transformation was also evident during culture in vitro, usually after 9–12 days. Oncogene complementation was also studied in the newborn rat brain. After microinjection of the retroviral vector into the brain at postnatal day (P)0, P1 and P3, 5 out of 20 animals (25%) developed a total of seven brain tumors. Histopathologically, three of these neoplasms were malignant neuroectodermal tumors which, in contrast to those induced in fetal brain transplants showed evidence of focal glial and/or neuronal differentiation. In addition, we observed one oligodendroglioma, two hemangiomas and a malignant hemangioendothelioma. These data indicate that neural precursor cells and endothelia of the rat brain represent the major target cells for the complementary action of ras and myc and that the use of target cells from later developmental stages (E16 and postnatal) leads to the induction of both primitive and more differentiated neoplasms.These studies were supported by the Fonds zur Förderung der wissenschaftlichen Forschung in Österreich (Erwin Schrödinger fellowship, JO501-MED), by the Swiss National Science Foundation and by the Cancer League of the Kanton of Zürich     

应用皮瓣移植修复足跟部皮肤软组织缺损

目的通过8种不同皮瓣的临床应用,总结足跟部皮肤软组织缺损的修复效果。方法采用了游离足背皮瓣、游离背阔肌皮瓣、游离肩胛皮瓣、桥式胫后动脉岛状皮瓣、桥式携带背阔肌皮瓣或桥式携带肩胛皮瓣、胫后动脉岛状皮瓣、胫后动脉皮支岛状皮瓣、跖底内侧动脉岛状皮瓣,对足跟部皮肤软组织缺损进行修复的临床应用。结果95块皮瓣修复足跟部皮肤软组织缺损,成活93块,成功率为97.9%。随访1～15年,治疗效果满意。结论应用皮瓣移植的方法,才能使足跟部皮肤软组织缺损得到有效的修复。     

Angiolymphoid hyperplasia with eosinophilia: report of a large-sized scalp lesion

In this report, a case is presented with large recurrent, benign, vascular and proliferative lesion on the scalp. Complete surgical excision of the tumor mass and split thickness skin grafting of the defect had favorable results with no recurrences after 24-month follow-up.     

小指固有伸肌腱移位术后小指伸直障碍的防治

目的 探讨小指固有伸肌腱移位术后小指伸直障碍的应用解剖学依据及其防治方法。方法 针对小指伸肌腱行解剖学观察158例标本，并将伸向小指的指总伸肌腱束按生物力学分类为四型：即标准型、力线偏离度小型、力线偏离度大型及缺如型；针对术后小指伸直障碍，用腱间纤维联系切断术治疗3例，术中预防性治疗55例。结果 经1年以上随访，1989年8月－1996年间的54例病例中，3例术后发生小指伸直不全，经腱间纤维联系切断术后均治愈，此后，采用术中预防性治疗后未再发生小指伸直障碍。结论 小指固有伸肌腱移位术后小指伸直障碍与伸向小指的指总伸肌腱束的力线有关，按其类型分别采用腱间纤维联系切断术、腱短缩术及腱重建术，能够有效地防治小指伸直障碍的发生。     

引导组织再生术促进牙槽骨再生的临床研究

目的观察引导组织再生术(guided tissue regeneragion,GTR)和Bio-plant HTR骨粉植骨术促进Ⅱ度根分叉病变患者牙糟骨再生的作用.方法使用Biomesh膜和 Bio-plant HTR骨粉对18例Ⅱ度根分叉病变行GTR手术和植骨术,手术前和手术后半年检查牙周袋深度、临床附着水平,摄数字化X光根尖片.结果术后半年18颗患牙牙周袋深度较术前明显变浅、附着水平明显增加(P＜0.01),术后半年的数字化X光根尖片与术前对比可见根分叉处暗影变小,牙槽骨密度明显增加,示有新骨形成.结论该方法对Ⅱ度根分叉病变有良好临床疗效.     

下颌升支后缘倒植自体真皮脂肪游离移植在颞颌关节重建中的临床应用

目的:观察下颌升支后缘倒植自体真皮脂肪游离移植重建颞颌关节的效果。方法:对12例颞颌关节强直,4例髁状突良性肿瘤,8例髁状突骨折应用此方法进行颞颌关节重建并进行随访分析。结果:22例患者经过1年~10年的临床随访,效果满意,均未发现关节强直。结论:下颌升支后缘倒植自体真皮脂肪游离移植重建颞颌关节是防止关节强直的有效方法。     

TIBIA AS DONOR SITE FOR ALVEOLAR BONE GRAFTING IN PATIENTS WITH CLEFT LIP AND PALATE: LONG TERM EXPERIENCE

Tibial bone grafts were studied in 137 patients with clefts of the lip and palate. Twenty-one had clefts of the lip and primary palate and 116 had complete unilateral clefts of the lip and palate. Bone grafting was performed secondarily or late secondarily. Bone was harvested from the proximal part of the tibia distal to the tuberosity through an incision about 15 mm long. The mean follow-up time after bone grafting was 5.5 years (range 2-11). There were no operative, or early or late postoperative complications reported (such as haematoma, fracture, or shortening of the limb). Harvesting time was about 15 minutes. The possibility of operating with two teams makes the total operating time shorter. Bleeding was negligible (less than 15 ml) and the amount of bone obtained was always sufficient. Patients were mobilised the next day and were back to full physical activity by one month. Indications for tibial bone grafting included facilitation of tooth eruption into the graft, giving bony support to the neighbouring teeth, making it possible to insert a titanium fixture, raising the alar base of the nose, and closing an oronasal fistula. Compared with iliac, cranial, mandibular, and costal donor sites, using the tibia took less time, gave less bleeding, made it possible for two teams to operate simultaneously, gave a smaller scar, and there were minimal complications and satisfactory quantity and quality of bone in all cases. The results suggested that the tibia is an excellent choice of graft for residual alveolar clefts in patients with cleft lip and palate.     

Soluble Adhesion Molecules in Coronary Surgery and Cardiopulmonary Bypass with Pump Prime Aprotinin

Objective : The purpose of the present study was to establish whether pump prime aprotinin could influence soluble adhesion molecules in patients undergoing elective coronary artery bypass surgery. Design : Thirty patients admitted for first-time elective coronary artery bypass surgery were randomized into control or aprotinin groups. Patients in the aprotinin group received 280 mg of aprotinin in the pump prime. Plasma levels of soluble adhesion molecules were analyzed perioperatively. Results : There were no significant changes in plasma sE-selectin after the operation in either group. Plasma sP-selectin increased significantly up to 20 h after reperfusion to the myocardium. Plasma sICAM-1 decreased in the early stage after cardiopulmonary bypass (CPB), then recovered at 4 h after reperfusion and a significant increase in sICAM-1 was observed 20 h later. There were no significant differences between the groups in postoperative changes in sP-selectin ( p = 0.21) and sICAM-1 ( p = 0.91). Conclusion : Pump prime aprotinin did not influence plasma levels of E-selectin, P-selectin and ICAM-1 in the present patients. The present results do not support the concept of an anti-inflammatory effect of pump prime aprotinin.